Research by Goal
Explore preclinical research on peptides and bioactive compounds grouped by research goal. Each page covers the studied compounds, mechanisms, and current evidence for that application.
Gut Healing
Your gut lining replaces itself every few days — a remarkable feat of biological engineering. But when damage outpaces repair, this barrier weakens. Everything below comes from preclinical research, and we'll flag exactly where the evidence ends. BPC-157 was discovered in human gastric juice precisely because it appears to play a fundamental role in this repair process [PMID: 21030672]. Unlike synthetic compounds designed in a lab, BPC-157 is derived from a protein your body already produces in the very environment where gut healing matters most.
Tendon Repair
Tendons have a problem: they need to withstand enormous force, yet they receive very little blood flow. This poor vascularization is why tendon injuries heal slowly and often incompletely [PMID: 25415472]. Two distinct peptides — BPC-157 and TB-500 — are being researched for their potential to address tendon repair from complementary angles. Below: how each works, what animal studies show — and where the evidence stops.
Wound Healing
What if the breakthrough in wound healing isn't a single molecule but the recognition that wounds need simultaneous solutions across multiple biological layers? Three entirely different peptides offer complementary approaches: BPC-157 amplifies growth signaling through mTOR and nitric oxide pathways [PMID: 21030672]; TB-500 reorganizes cellular architecture and builds new blood vessels [PMID: 16099219]; GHK-Cu directly stimulates the structural proteins damaged tissue needs [PMID: 26236730]. This is not redundancy — it's the recognition that wound healing is fundamentally a multi-system problem. Every result below, though, comes from preclinical research — flagged honestly as we go.
Injury Recovery
Here's a question most injury conversations skip: why does some tissue heal while structurally similar tissue doesn't? The difference isn't luck — it's whether the biological repair machinery receives the right signals at the right time. BPC-157 and TB-500 approach this problem from opposite but complementary directions: BPC-157 research suggests it amplifies the cellular growth cascade through mTOR and nitric oxide pathways [PMID: 21030672], while TB-500 studies indicate it builds the vascular and structural scaffolding that regenerating tissue desperately requires [PMID: 16099219]. Understanding both reveals why researchers explore them not as competitors but as potential sequential partners in recovery. All of the evidence below is preclinical — flagged clearly as we go.
Skin Health
Your skin contains a repair mechanism that operates less efficiently with each passing year. That decline has a name: falling levels of GHK-Cu, a naturally occurring copper peptide found in human plasma, saliva, and wound fluid [PMID: 26236730]. Research suggests this endogenous compound may reactivate the machinery responsible for collagen synthesis, antioxidant defense, and tissue remodeling — processes that slow dramatically as chronological age advances. What makes GHK-Cu unusual in peptide research is that the question isn't whether a foreign molecule helps — everything below is preclinical, flagged as we go — but whether restoring one of your own molecules can reverse certain aging phenotypes at the tissue level.
Anti-Aging
Aging is not a single biological event — it is a constellation of parallel declines across multiple systems. Two distinct research pathways dominate the anti-aging peptide conversation, and they address fundamentally different layers of the problem. GHK-Cu acts locally on skin fibroblasts to support collagen synthesis and antioxidant defense — targeting the visible structural changes that accompany chronological aging [PMID: 26236730]. CJC-1295 and Ipamorelin operate systemically on the growth hormone (GH) axis, addressing the hormonal decline known as somatopause, in which GH secretion falls by roughly a third to a half between ages 20 and 60 — picture running on about half your youthful anabolic signaling by 60 [PMID: 16352683]. The local-versus-systemic distinction is the key to why researchers explore them separately and, occasionally, together. Each section below flags its own evidence level.
Muscle Growth
Most people assume growth hormone builds muscle directly. Here's the biological plot twist: it doesn't — GH signals the liver to produce IGF-1, which then acts on muscle tissue itself [PMID: 16352683]. This two-step relay system is what makes CJC-1295 and Ipamorelin such a frequently paired combination in muscle research conversations. Understanding the chain comes before evaluating the compounds — and note that most of the evidence below is preclinical, flagged as we go.
Fat Loss
Growth hormone does something unusual: it mobilizes stored fat while simultaneously driving anabolic processes in muscle [PMID: 16352683]. This creates a metabolic state rarely achieved by other compounds — tissues being asked to build and burn at the same time. Understanding this paradox is the starting point for evaluating CJC-1295 and Ipamorelin in fat-loss research, where most evidence remains preclinical — flagged as we go.
Weight Loss
Most weight-loss conversations in 2026 center on GLP-1 receptor agonists. But there is a separate metabolic pathway worth understanding: growth hormone signaling, which influences body composition through lipolysis rather than appetite suppression [PMID: 16352683]. CJC-1295 and Ipamorelin sit at the center of this alternative mechanism — one that works on fat cells themselves rather than on hunger signals in the brain. The evidence below is mostly preclinical; each section flags where it stands.
Joint Pain
Joint pain sits at the intersection of inflammation, tissue damage, and repair capacity — and peptides approach this complexity from completely different angles. BPC-157 was discovered in gastric fluid but shows remarkable effects on tendon and ligament healing [PMID: 21030672], while TB-500 governs the structural scaffolding that cells use to migrate and rebuild. Understanding their distinct mechanisms is essential before evaluating them together — and note upfront: nearly everything below is preclinical.
Sleep
You fall asleep exhausted and wake up like the night never counted. Deep sleep is when growth hormone secretion peaks — the hours when tissue repair and metabolic restoration run hardest [PMID: 16352683]. Could compounds that modulate the GH axis make those hours count for more? That preclinical question drives this page, limits flagged as we go.
Longevity
Longevity research increasingly recognizes that aging is not one problem but many — and effective interventions must address multiple layers simultaneously. Three peptides offer distinct mechanisms that target aging at different biological levels [PMID: 26236730] [PMID: 16352683]: GHK-Cu at the cellular level, supporting collagen synthesis and antioxidant defense; CJC-1295 and Ipamorelin systemically, addressing the hormonal decline of aging. Together they represent a multi-target approach to age-related decline — with one caveat, noted as we go: every piece of evidence below is preclinical.
Inflammation
Knees that stay swollen after workouts, a gut that flares no matter what you eat — chronic inflammation is the alarm that never switches off. Peptide research is exploring how to modulate inflammatory checkpoints precisely rather than blunting the whole system. BPC-157 and TB-500 approach that problem through different molecular doors. All of it is preclinical so far — flagged honestly as we go.
Recovery
Three days after a brutal training week, you're still the person who can't train — and everyone has an opinion on how to recover faster. Biology has a more precise answer: recovery is an active process of repair, rebuilding, and adaptation. BPC-157 and TB-500 approach that process from complementary directions — one amplifying growth signals, the other building the infrastructure regeneration travels on [PMID: 25415472] [PMID: 20691219]. Nearly all of the evidence below is preclinical, and we'll keep flagging exactly how much.
Brain Health
The brain guards itself fiercely — and that guard system is exactly what makes neurological research so difficult. When oxidative stress or neuroinflammation tips neurotransmitter signaling off balance, cognitive function can decline in ways researchers are still working to understand [PMID: 21030672]. Two peptides — BPC-157 and GHK-Cu — are being studied for brain health through different mechanisms, both facing the same fortress problem. Everything here is preclinical; the flags start now.
Immune Support
Your immune system fights a daily balancing act: attack threats hard enough to win, restrain itself enough to spare healthy tissue. TB-500 and GHK-Cu approach that balancing act from opposite ends — one influencing how immune cells move and how inflammation resolves, the other supporting the antioxidant defenses that keep activated immune cells from damaging their surroundings [PMID: 20691219] [PMID: 26236730]. Both stories remain preclinical, as every section makes clear.
All research on this site is preclinical unless otherwise noted. Evidence comes from animal models and in vitro studies. None of this constitutes medical advice.